Project Grant K01DA061973
- The U.S. National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $686,692 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Medical University of South Carolina. The grant will fund an 8-week clinical trial to assess the prospective changes in patient-reported and objective functioning following reduction of cannabis use among adults with cannabis use disorder. The trial will evaluate the benefits of cannabis harm...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- This federal Project Grant award of $385,638 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the grant is to conduct research on the neurobehavioral consequences of chronic exposure to synthetic cannabinoids, also known as "synthetic marijuana", across different stages of lifespan development and between sexes. The research aims to elucidate the...
- This federal Project Grant award of $450,313 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the influence of psychotherapeutic advertising claims and mental health warning labels on online cannabis purchasing behaviors among individuals with symptoms of depression and/or anxiety. The project, titled "Evaluating the Impact of Psychotherapeutic Advertising Claims on Cannabis Purchasing," will...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $334,343 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Syncanica Bio, Inc. on June 15, 2025. The goal of this award is to develop and market a synthetic analog of 8,9-dihydrocannabidiol (H2CBD) as a therapeutic agent for the treatment of substance use disorder, a significant public health crisis. This builds upon Syncanica Bio's existing research on the...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $639,920 project grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Board of Regents of the Nevada System of Higher Education, operating through the University of Nevada, Reno. The grant, which runs from September 15, 2025 to May 31, 2030, will fund a human laboratory study to examine the influence of "natural" cigarillo descriptors on expectancies, subjective...
- This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research on the impact of oral THC consumption during adolescence on the adult mouse brain. The $716,455 award, effective July 1, 2025 through March 31, 2030, will enable researchers at the University of Washington to: Determine how long-term adolescent use of THC-gelatin, alone or in combination with cannabidiol (CBD), impacts...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $1,320,580 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in Missouri. The grant will fund preclinical studies to evaluate the analgesic potential of a novel, peripherally-restricted cannabinoid type 1 receptor (CB1R) agonist called VIP36. The key objectives are to assess VIP36's efficacy in mouse models of post-traumatic headache,...
- This $507,000.00 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at the Icahn School of Medicine at Mount Sinai to investigate the epigenetic mechanisms underlying cannabis use disorder. The project, running from September 1, 2025 to May 31, 2030, aims to leverage a translational animal model of voluntary THC consumption to study sex differences and individual variability in...
- This Project Grant award of $153,000.00, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a 6-month longitudinal study examining the relationships between naturalistic cannabis use, pain perception, and functioning (e.g., pain-related disability, physical activity, sleep) in the daily lives of young adults with chronic pain. The study will use an ecological momentary assessment burst design to capture...
The National Institute on Drug Abuse (NIDA) has awarded a $159,139 Project Grant to George Washington University (GWU) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant, awarded on August 15, 2025, will support research on the "Impact of Derived Psychoactive Cannabis Product Marketing on Perceptions and Use Among Young Adults." This project aims to investigate the effects of the marketing and availability of cannabis products on usage patterns and perceptions among young adults, especially given the increasing legalization of non-medical cannabis in many states. The research will be conducted at GWU and is expected to be completed by July 31, 2030. This grant represents NIDA's investment in understanding the public health implications of the evolving cannabis market in the United States.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $159.1k | 8/14/25 |